These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 15088033)

  • 1. Oral graft-versus-host disease and programmed cell death: pathogenetic and clinical correlates.
    Sedghizadeh PP; Allen CM; Anderson KE; Kim DH; Kalmar JR; Lang JC
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2004 Apr; 97(4):491-8. PubMed ID: 15088033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Salivary gland involvement in graft-versus-host disease: the underlying mechanism and implicated treatment.
    Nagler RM; Nagler A
    Isr Med Assoc J; 2004 Mar; 6(3):167-72. PubMed ID: 15055275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recognition, incidence, and management of oral graft-versus-host disease.
    Schubert MM; Sullivan KM
    NCI Monogr; 1990; (9):135-43. PubMed ID: 2188151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Graft-versus-host disease, an eight case report and literature review.
    de la Rosa García E; Bologna Molina R; Vega González Tde J
    Med Oral Patol Oral Cir Bucal; 2006 Nov; 11(6):E486-92. PubMed ID: 17072252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Gran versus host disease with oral involvement: report of one case].
    Rojas A G; González G N; Venables G C; Araos H D
    Rev Med Chil; 2008 Dec; 136(12):1570-3. PubMed ID: 19350175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topical cyclosporin A for treatment of oral chronic graft-versus-host disease.
    Epstein JB; Reece DE
    Bone Marrow Transplant; 1994 Jan; 13(1):81-6. PubMed ID: 8019458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral graft-versus-host disease.
    Schubert MM; Correa ME
    Dent Clin North Am; 2008 Jan; 52(1):79-109, viii-ix. PubMed ID: 18154866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lichenoid graft-vs-host disease in an autologous bone marrow transplant recipient.
    Martin RW; Farmer ER; Altomonte VL; Vogelsang GB; Santos GW
    Arch Dermatol; 1995 Mar; 131(3):333-5. PubMed ID: 7887664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical characteristics of chronic cutaneous graft-versus-host disease in Japanese leukemia patients after bone marrow transplantation: low incidence and mild manifestations of skin lesions.
    Fujii H; Hiketa T; Matsumoto Y; Ohashi M; Miyamura Y; Tanimoto M; Morishima Y; Saito H; Horibe K; Shibata Y
    Bone Marrow Transplant; 1992 Oct; 10(4):331-5. PubMed ID: 1422488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation.
    Schwinghammer TL; Bloom EJ
    Clin Pharm; 1993 Oct; 12(10):736-61. PubMed ID: 8258255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T-cell frequency analysis does not predict the incidence of graft-versus-host disease in HLA-matched sibling bone marrow transplantation.
    Wang XN; Taylor PR; Skinner R; Jackson GH; Proctor SJ; Hedley D; Dickinson AM
    Transplantation; 2000 Aug; 70(3):488-93. PubMed ID: 10949192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Keratinocyte apoptosis following bone marrow transplantation: evidence for CTL-dependent and -independent pathways.
    Jerome KR; Conyers SJ; Hansen DA; Zebala JA
    Bone Marrow Transplant; 1998 Aug; 22(4):359-66. PubMed ID: 9722071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteopontin attenuates acute gastrointestinal graft-versus-host disease by preventing apoptosis of intestinal epithelial cells.
    Kawakami K; Minami N; Matsuura M; Iida T; Toyonaga T; Nagaishi K; Arimura Y; Fujimiya M; Uede T; Nakase H
    Biochem Biophys Res Commun; 2017 Apr; 485(2):468-475. PubMed ID: 28192120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lichenoid chronic graft-vs-host disease occurring in a dermatomal distribution.
    Freemer CS; Farmer ER; Corio RL; Altomonte VL; Wagner JE; Vogelsang GB; Santos GW
    Arch Dermatol; 1994 Jan; 130(1):70-2. PubMed ID: 8285743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical identification of perforin-positive cytotoxic lymphocytes in graft-versus-host disease.
    Takata M
    Am J Clin Pathol; 1995 Mar; 103(3):324-9. PubMed ID: 7872255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
    Talmadge JE
    Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Chronic graft-versus-host-disease involving the oral mucosa: clinical presentation and treatment].
    Elad S; Levitt M; M Y S
    Refuat Hapeh Vehashinayim (1993); 2008 Nov; 25(4):19-27, 72. PubMed ID: 19263864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic intestinal graft-versus-host disease: clinical, histological and immunohistochemical analysis of 17 children.
    Patey-Mariaud de Serre N; Reijasse D; Verkarre V; Canioni D; Colomb V; Haddad E; Brousse N
    Bone Marrow Transplant; 2002 Feb; 29(3):223-30. PubMed ID: 11859394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Canine Model of Chronic Graft-versus-Host Disease.
    Graves SS; Rezvani A; Sale G; Stone D; Parker M; Rosinski S; Spector M; Swearingen B; Kean L; Storb R
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):420-427. PubMed ID: 28013013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.